Abstract
Background/Aims: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by meta-analysis. Methods: The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of evidence was assessed using the grading of recommendations assessment, development and evaluation guidelines. Results: Three RCTs (n = 98) and two NRSs (n = 101) met our study inclusion criteria (adult, NAFLD, liver biopsy). Liver biopsy was performed in all five studies, but only the three studies reported NAS. Ezetimibe significantly decreased NAS (standardized mean difference [SMD], –0.30; 95% confidence interval [CI], –0.57 to –0.03) but not hepatic steatosis in RCT (SMD, –0.1; 95% CI, –0.53 to 0.32), while the effect was significant for both NAS and intrahepatic content in NRSs (SMD, –3.0; 95% CI, –6.9 to 0.91). Conclusions: Ezetimibe decreased NAS without improving hepatic steatosis.
| Original language | English |
|---|---|
| Pages (from-to) | 296-304 |
| Number of pages | 9 |
| Journal | Korean Journal of Internal Medicine |
| Volume | 34 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2019 Mar 1 |
Fingerprint
Keywords
- Ezetimibe
- Hydroxymethylglu-taryl-CoA reductase inhibitors
- Meta-analysis
- Non-alcoholic fatty liver disease
ASJC Scopus subject areas
- Internal Medicine
Cite this
Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. / Lee, Hyo Young; Jun, Dae Won; Kim, Hyun Jung; Oh, Hyunwoo; Saeed, Waqar Khalid; Ahn, Hyeong Sik; Cheung, Ramsey C.; Nguyen, Mindie H.
In: Korean Journal of Internal Medicine, Vol. 34, No. 2, 01.03.2019, p. 296-304.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
AU - Lee, Hyo Young
AU - Jun, Dae Won
AU - Kim, Hyun Jung
AU - Oh, Hyunwoo
AU - Saeed, Waqar Khalid
AU - Ahn, Hyeong Sik
AU - Cheung, Ramsey C.
AU - Nguyen, Mindie H.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Background/Aims: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by meta-analysis. Methods: The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of evidence was assessed using the grading of recommendations assessment, development and evaluation guidelines. Results: Three RCTs (n = 98) and two NRSs (n = 101) met our study inclusion criteria (adult, NAFLD, liver biopsy). Liver biopsy was performed in all five studies, but only the three studies reported NAS. Ezetimibe significantly decreased NAS (standardized mean difference [SMD], –0.30; 95% confidence interval [CI], –0.57 to –0.03) but not hepatic steatosis in RCT (SMD, –0.1; 95% CI, –0.53 to 0.32), while the effect was significant for both NAS and intrahepatic content in NRSs (SMD, –3.0; 95% CI, –6.9 to 0.91). Conclusions: Ezetimibe decreased NAS without improving hepatic steatosis.
AB - Background/Aims: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by meta-analysis. Methods: The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of evidence was assessed using the grading of recommendations assessment, development and evaluation guidelines. Results: Three RCTs (n = 98) and two NRSs (n = 101) met our study inclusion criteria (adult, NAFLD, liver biopsy). Liver biopsy was performed in all five studies, but only the three studies reported NAS. Ezetimibe significantly decreased NAS (standardized mean difference [SMD], –0.30; 95% confidence interval [CI], –0.57 to –0.03) but not hepatic steatosis in RCT (SMD, –0.1; 95% CI, –0.53 to 0.32), while the effect was significant for both NAS and intrahepatic content in NRSs (SMD, –3.0; 95% CI, –6.9 to 0.91). Conclusions: Ezetimibe decreased NAS without improving hepatic steatosis.
KW - Ezetimibe
KW - Hydroxymethylglu-taryl-CoA reductase inhibitors
KW - Meta-analysis
KW - Non-alcoholic fatty liver disease
UR - http://www.scopus.com/inward/record.url?scp=85062613880&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062613880&partnerID=8YFLogxK
U2 - 10.3904/kjim.2017.194
DO - 10.3904/kjim.2017.194
M3 - Article
VL - 34
SP - 296
EP - 304
JO - Korean Journal of Internal Medicine
JF - Korean Journal of Internal Medicine
SN - 0494-4712
IS - 2
ER -